P Stamoulos, A Ansari, J Stenner, G Mackenzie… - Gut, 2011 - gut.bmj.com Introduction In Inflammatory bowel disease (IBD) lack of response or side effects to thiopurines (TP: azathioprine and mercaptopurine) are common (30–50%) and frequently necessitate surgery or use of biologic agents (£10 000–15 000/patient/year). It is assumed that low dose ...
GE Dolman, HE Johnson, SD McLaughlin… - Gut, 2011 - gut.bmj.com Introduction Azathioprine is widely used in the management of Inflammatory Bowel Disease (IBD). The ideal dose for a patient is usually calculated by weight, but the rate of metabolism of azathioprine to its active metabolite 6-thioguanine (6TGN) varies between individuals. ... All 3 versions
HE Johnson, SD McLaughlin… - Gut, 2011 - gut.bmj.com Methods A prospective data base of IBD patients has been maintained at our unit since 2005. The authors reviewed the cases of all IBD patients commencing azathioprine treatment between June 2005 and December 2007 and followed up for at least 3 years. Thiopurine ...
RJ Anderson, HK Dhaliwal, S Schneider… - Gut, 2011 - gut.bmj.com Introduction Long term azathioprine (AZA, 2 mg/kg/day) is used to maintain remission in Autoimmune Hepatitis (AIH). However 10–20% of patients are unresponsive to AZA. AZA is a pro-drug and formation of the active metabolite (thioguanine nucleotides-TGNs) varies between ...
M Shipkova, J Franz, M Abe, C Klett… - Therapeutic Drug …, 2011 - journals.lww.com Wolters Kluwer Health may email you for journal alerts and information, but is committed to maintaining your privacy and will not share your personal information without your express consent. For more information, please refer to our Privacy Policy. ... Skip Navigation Links Home > Current ... Related articles - All 4 versions
沪公网安备号：31010402006960 （网站）31010405000484 （蝌蝌APP）
安全保密
